Published in Am J Transl Res on April 21, 2011
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget (2011) 1.31
EZH2 in normal and malignant hematopoiesis. Leukemia (2013) 1.28
Genetic syndromes caused by mutations in epigenetic genes. Hum Genet (2013) 1.11
Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res (2015) 1.04
PRC2 during vertebrate organogenesis: a complex in transition. Dev Biol (2012) 1.04
Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med (2014) 0.97
Dynamic changes in Ezh2 gene occupancy underlie its involvement in neural stem cell self-renewal and differentiation towards oligodendrocytes. PLoS One (2012) 0.96
Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol Med (2013) 0.92
Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc Natl Acad Sci U S A (2015) 0.87
The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. J Pathol (2014) 0.86
Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the β-catenin gene. J Biol Chem (2014) 0.85
EZH2 in normal hematopoiesis and hematological malignancies. Oncotarget (2016) 0.81
Post-Translational Modifications of Histones in Vertebrate Neurogenesis. Front Neurosci (2015) 0.78
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget (2016) 0.78
Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells. Stem Cells Dev (2016) 0.77
Mdm2 as a chromatin modifier. J Mol Cell Biol (2016) 0.77
The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells. Stem Cells Int (2016) 0.76
Association of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigma. Transl Neurosci (2015) 0.75
The association and significance of H3K27me3 and a folate metabolic gene ACat2 in neural tube defects. Nutr J (2016) 0.75
Signals of Ezh2, Src, and Akt Involve in myostatin-Pax7 pathways regulating the myogenic fate determination during the sheep myoblast proliferation and differentiation. PLoS One (2015) 0.75
Chromatin state dynamics during NK cell activation. Oncotarget (2017) 0.75
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev (2006) 14.36
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer (2006) 11.48
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J (2004) 7.32
The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol (2001) 7.20
Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res (2008) 6.46
The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev (2004) 6.20
Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol (2002) 5.67
Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell (2009) 5.51
Polycomb complexes and epigenetic states. Curr Opin Cell Biol (2008) 3.81
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev (2010) 3.49
Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol (2010) 3.16
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem (2008) 2.81
MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem (2003) 2.78
Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development (2009) 2.69
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol (2010) 2.64
Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell (2009) 2.47
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol (2010) 2.36
Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. Neuron (2009) 2.16
Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells (2007) 2.05
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis (2010) 1.98
Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A (2010) 1.97
EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J Biol Chem (2005) 1.93
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget (2010) 1.92
MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer (2010) 1.87
Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci U S A (2010) 1.83
Loss of hematopoietic stem cell self-renewal after bone marrow transplantation. Blood (1989) 1.45
cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS One (2008) 1.36
High histone acetylation and decreased polycomb repressive complex 2 member levels regulate gene specific transcriptional changes during early embryonic stem cell differentiation induced by retinoic acid. Stem Cells (2007) 1.32
Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol (2008) 1.31
TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS One (2010) 1.28
Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2. Stem Cells (2008) 1.26
Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. J Immunol (2001) 1.20
The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatol (2010) 1.16
Histone modifications dictate specific biological readouts. J Genet Genomics (2009) 1.15
EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. Epigenetics Chromatin (2009) 1.05
EZH2 regulates neuronal differentiation of mesenchymal stem cells through PIP5K1C-dependent calcium signaling. J Biol Chem (2011) 1.03
Role of the polycomb group proteins in hematopoietic stem cells. Dev Growth Differ (2010) 1.00
Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics (1996) 0.97
Selective control of Pax7 expression by TNF-activated p38α/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. Cell Cycle (2011) 0.93
Epigenetic control of hematopoietic stem cell aging the case of Ezh2. Ann N Y Acad Sci (2007) 0.93
Modulation of osteogenesis and adipogenesis by human serum in human bone marrow cultures. Eur J Cell Biol (1997) 0.93
Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression. J Pineal Res (2010) 0.92
Ezh2 expression in astrocytes induces their dedifferentiation toward neural stem cells. Cell Reprogram (2010) 0.91
Hematopoietic stem cells: source matters. Curr Stem Cell Res Ther (2008) 0.86
Phosphoryl-EZH-ion. Cell Stem Cell (2011) 0.84
Placenta as a newly identified source of hematopoietic stem cells. Curr Opin Hematol (2010) 0.82
Lymphoid lineage fate decision of hematopoietic stem cells. Ann N Y Acad Sci (2009) 0.82
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 3.85
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell (2007) 3.42
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08
TRIM24 links a non-canonical histone signature to breast cancer. Nature (2010) 2.99
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature (2013) 2.67
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62
Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res (2005) 2.58
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) (2010) 2.57
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res (2004) 2.48
Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol (2006) 2.45
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol (2010) 2.36
beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell (2002) 2.33
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30
Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem (2007) 2.30
A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res (2009) 2.27
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med (2012) 2.24
Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol (2005) 2.20
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem (2006) 2.11
Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res (2007) 2.10
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell (2009) 2.09
Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res (2007) 2.02
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res (2012) 1.97
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med (2010) 1.95
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst (2002) 1.95
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat (2006) 1.92
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem (2003) 1.88
Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res (2008) 1.88
Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene (2007) 1.86
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell (2009) 1.85
Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog (2006) 1.78
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res (2004) 1.76
MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol (2006) 1.75
14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res (2009) 1.74
Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res (2009) 1.74
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell (2010) 1.71
RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol (2012) 1.69
Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol (2009) 1.67
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell (2002) 1.67
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res (2002) 1.58
Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle (2005) 1.57
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res (2008) 1.56
Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell (2012) 1.54
Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem (2011) 1.52
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res (2005) 1.51
p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem (2009) 1.48
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Invest (2014) 1.45
Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res (2009) 1.44
Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res (2006) 1.43
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol (2010) 1.42
A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res (2005) 1.41
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol (2011) 1.40
Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Res (2007) 1.38
All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle (2007) 1.38
Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res (2008) 1.37
The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem (2010) 1.36
Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell (2007) 1.35
Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res (2012) 1.33
Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem (2009) 1.32
IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell (2011) 1.32
Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther (2004) 1.32
Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol Carcinog (2004) 1.31